← All trials
NCT04395092
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 31, 2020
- Primary completion
- Dec 31, 2022
- Completion date
- Mar 31, 2023
- First posted
- May 20, 2020
- Last posted
- May 20, 2020
- Enrollment
- 63
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Kiadis PharmaLead sponsor
- National Institutes of Health (NIH)Collaborator
- National Cancer Institute (NCI)Collaborator
- National Heart, Lung, and Blood Institute (NHLBI)Collaborator
- Ohio State UniversityStudy chair
- University of Texas at HoustonStudy chair
- Blood and Marrow Transplant Clinical Trials NetworkCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.